5月8日 - ** 疫苗生产商 Novavax NVAX.O 股价盘前上涨 28.9% 至 7.67 美元
** 该公司第一季度从去年同期的亏损转为盈利，这得益于其 COVID-19 疫苗开发和销售成本的降低
** 称正在与美国 FDA 讨论 COVID-19 疫苗的研究设计方案
** 报告第一季度净收入为 5.19 亿美元，而去年同期净亏损为 1.48 亿美元
** 一季度营收为6.67亿美元，高于去年同期的9400万美元，超过分析师预计的3.4385亿美元，数据来源于LSEG汇编的数据
** 上个月，美国卫生监管机构要求诺瓦克斯提供更多有关其 COVID-19 疫苗的数据，如果该疫苗获得全面批准的话。
** 截至上次收盘，NVAX 年累计下跌 26
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.